At the same time, AS deregulation increases the sensitivity of CRPC, as well as several other tumour types, to the anti-tumoral activity of inhibitors of the splicing process and of transcriptional kinases, such as CDK12/13 [7, 12, 19, 25]. The gene discussed is CDK12; the disease is neoplasm.